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Introduction
One of the fundamental roles of prenatal diagnosis is
the timely antenatal detection of common chromo-
somal pathologies, such as trisomy 21 [1]. However, the
exact diagnosis of fetal chromosomal abnormalities re-
quires cytogenetic studies. Although noninvasive diag-
nosis using fetal cells from maternal plasma and nucleic
acid assessment has been under investigation for almost
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SUMMARY
Objective: To investigate the relationship between two novel first-trimester ultrasound markers (abnormal fetal
ductus venosus [DV] flow and presence of tricuspid regurgitation [TR]) and the results of the first-trimester
combined screening test in pregnancies with a normal karyotype. The screening test involves nuchal translu-
cency measurement by ultrasound, and measurement of serum free β-chorionic gonadotropin and pregnancy-
associated plasma protein A.
Materials and Methods: The study included 58 pregnancies with amniocentesis-proven normal karyotypes and
ultrasound-proven normal fetal anatomy. DV flow and TR were initially evaluated by ultrasound at 11–14
weeks’ gestation. Sensitivity, specificity, and positive and negative predictive values of abnormal DV flow and TR
for determining increased test risk (> 1 in 300) were calculated.
Results: Abnormal DV flow and TR were detected in seven (12%) and six (10%) women, respectively. The sensi-
tivities of abnormal DV flow, TR, and dual abnormalities (abnormal DV flow plus TR) for predicting increased
risk in the combined screening test were low (33.3%, 27.7%, and 26.3%, respectively). However, their correspon-
ding specificities (97.5%, 97.5%, and 100%) and positive predictive values (85.7%, 83.3%, and 100%) were 
reasonably high, with particularly low false-positive rates (2.5%, 2.5%, and 0%). When abnormal DV flow and
TR were both positive, the combined test risk was consistently above 1 in 300.
Conclusion: Determination of DV flow and TR as initial markers in unselected pregnancies merits further inves-
tigation, as the combination of these parameters might reliably predict an increased risk in combined screening
test result, with low false positivity. [Taiwan J Obstet Gynecol 2010;49(2):145–150]
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three decades, these technologies are still not in routine
clinical use [2]. Chorionic villus sampling and genetic
amniocentesis, therefore, continue to provide the main-
stay of prenatal diagnosis for chromosomal defects,
until noninvasive techniques become adopted for rou-
tine clinical use.
The major aim of antenatal screening tests is to
decrease the rate of invasive diagnostic procedures.
Current screening tests generally include biochemi-
cal assays and assessment of ultrasound markers.
Biochemical assessments include measurements of
pregnancy-associated plasma protein A (PAPP-A) and
free β-chorionic gonadotropin (β-hCG) in the first
trimester, and α-fetoprotein, β-hCG and estriol in the
second trimester.
Conventional combined first-trimester screening
(nuchal translucency [NT] plus PAPP-A plus free β-
hCG) has been considered to be an accurate test for
the detection of trisomy 21, with 90% sensitivity and a
5% false-positive rate. Additional ultrasound markers
have recently been added to the tests, with the aim of
further reducing the invasive procedure rate. These in-
clude NT, presence/absence of nasal bone, frontomax-
illary facial angle, normal/abnormal a wave in ductus
venosus (DV) Doppler flow analysis, and presence/
absence of tricuspid regurgitation (TR) [3–8].
The addition of DV Doppler flow analysis and TR to
the test results in similar sensitivity (about 90%), but
appears to improve the false-positive rate (2–9%) for
trisomy 21 detection [8,9]. Although DV and TR have
been evaluated as adjuncts to first-trimester screening
tests, their use as an initial step in the screening algorithm
is not clear. The present pilot study aimed to analyze the
relationship between these two novel ultrasound mark-
ers (DV and TR) and the results of the first-trimester
combined test (with NT, PAPP-A, and free β-hCG) in
singleton pregnancies with normal karyotypes.
Materials and Methods
The initial study included low-risk singleton pregnancies
at 11+0 to 13+6 weeks of gestation during an 18-month
period. Women were initially scanned by ultrasound to
determine crown-rump length and basic anatomy. NT
measurements, DV Doppler flow analysis and pulsed
Doppler analysis for TR were then obtained. The indi-
vidual risks were calculated based on NT values com-
bined with maternal serum PAPP-A and free β-hCG
measurements taken on the day of the ultrasound scan.
DV and TR results were not used to calculate the com-
bined risk. The study was subject to local ethics review
committee approval.
The aim of the present pilot study was to evaluate
only healthy pregnancies with no karyotype or structural
abnormalities. We, therefore, excluded any pregnan-
cies if: (1) the fetal NT measurement was > 2.5 mm;
(2) any structural abnormalities were detected or sus-
pected on ultrasound at 11–14 or 21–23 weeks’ gesta-
tion (including second-trimester markers for aneuploidy,
such as increased nuchal fold (> 6 mm), short long
bones (< 5th percentile), and single umbilical artery);
(3) normal fetal karyotype results could not be con-
firmed or were unavailable; or (4) routine follow-up
until term was missing. Karyotype abnormalities were
excluded by amniocentesis (at 16–19 weeks of gesta-
tion). Chorionic villus sampling was not routinely per-
formed during the study period.
Initially, 1,050 women scanned in the 11+0 to 13+6
weeks of pregnancy were enrolled during the 18-month
period. After exclusions, 66 women with fetal karyotype
reports were available. Eight women were further ex-
cluded; one had confirmed aneuploidy (trisomy 21),
and seven others were lost to follow-up after 20 weeks’
gestation. The remaining 58 women comprised our
study group.
All ultrasound scans were performed by one of the
investigators (O.O.) using the same machine (GE
Voluson 730 Expert; GE Medical Systems Kretztechnik
GmbH & Co, Zipf, Austria). NT measurements were
obtained as defined previously [10]. The midsagittal
plane view and fetal tissue–amniochorionic membrane
discrimination were meticulously visualized. DV Doppler
waveform analyses were performed as previously des-
cribed [11]. Briefly, the waveform was obtained at the
right ventral midsagittal plane during fetal quiescence
using pulsed Doppler flow. If necessary, color Doppler
mapping of the DV was obtained. Discrimination of the
inferior vena cava, left hepatic vein and intrahepatic
portion of the umbilical vein was specifically considered.
DV flow was recorded as “normal” or “abnormal”.
Absence of or reversed flow during atrial contraction
(a wave) was considered as abnormal.
TR was determined as described previously [10,12].
Briefly, a four-chamber view of the heart, aortic out-
flow and axis were first visualized. A pulsed Doppler
gate was then located towards the apical mid-portion
of the tricuspid valve in the four-chamber view, and the
Doppler waveform was obtained. Three consecutive
measurements were made. The diagnosis of TR required
two distinct criteria to be met: (1) regurgitation during
at least half of the systole, and (2) regurgitating flow
rate ≥ 60 cm/s. Other details of the technique have
been described elsewhere [10].
PAPP-A and free β-hCG measurements were per-
formed using an Immulite 2000 Immunoassay System
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(Siemens Healthcare Diagnostics, Deerfield, IL, USA),
using L2KPC2 and L2KFB2 assay kits. PRISCA Prenatal
Risk Calculation Software version 4.0 (Siemens Health-
care Diagnostics) was used to evaluate the risk.
The decision to perform an invasive procedure (i.e.
amniocentesis) depended on the woman’s decision fol-
lowing a detailed consultation with both partners based
on the first-trimester screening results. This included
information on trisomy 21, evaluation of the test re-
sults, and information on the risks involved in the inva-
sive procedure. The decision to perform an invasive
procedure did not depend solely on any specific cut-off
value. The women and their partners signed a written
consent form. Amniocentesis procedures were per-
formed abdominally under ultrasound guidance using
a 22-gauge needle. About 20 mL of amniotic fluid was
aspirated and sent for karyotype analysis by routine
cell culture. Women in the study group also underwent
ultrasound scanning at 21–23 weeks’ gestation. This
included detailed fetal anatomy and fetal cardiac scan-
ning. Four-chamber view, three-vessel view, outflow
tracts, arterial duct, and aortic arch were routinely
visualized.
Correlation between DV-tricuspid valve Doppler
flow results and the reported risk in the combined test
(NT plus PAPP-A plus free β-hCG) at 11–14 weeks’
gestation was examined in 58 singleton pregnancies
with amniocentesis-proven normal karyotypes and
ultrasound-proven normal fetal anatomy. The sensitiv-
ity, specificity, positive predictive value (PPV), negative
predictive value, false-negative rate, false-positive rate,
positive likelihood ratio, negative likelihood ratio, and
accuracy rate of abnormal DV flow and TR for deter-
mining a screen-positive test result were calculated
(cut-off value, > 1 in 300). Statistical analyses were per-
formed using the “descriptive tests module” in SPSS
version 15.0 software (SPSS, Chicago, IL, USA).
Results
The mean (± standard deviation) age, gravidity, and
parity were 30.2 ± 6.2 years, 1.9 ± 0.9, and 0.7 ± 0.7,
respectively (n = 58). Indications for genetic amnio-
centesis are shown in Table 1. Advanced maternal age
and maternal anxiety were the most frequent indica-
tions (53%).
Abnormal DV flow and TR were present in 12% 
(7 of 58) and 10% (6 of 58) of pregnancies, respec-
tively. Five fetuses had abnormal DV flow accompa-
nied by TR. Two pregnancies had abnormal DV flow
and normal tricuspid flow. One case had TR but normal
DV flow.
The distributions of pregnancies with abnormal DV
flow, presence of TR, and presence of abnormal DV
flow accompanied by TR are given in Table 2. Table 3
summarizes the efficacy of the studied ultrasound pa-
rameters for the prediction of increased risk (> 1 in 300)
in the first-trimester screening test. Generally, abnor-
mal DV flow and TR had low sensitivities (33.3%, and
27.7%, respectively) but exceedingly high specificities
(both 97.5%) with low false-positive rates (both 2.5%)
for the prediction of an “increased risk” result. When
both of the ultrasound markers (DV and TR) were pos-
itive, the combined test risk was consistently above 1 in
300 (PPV, 100%; Table 3).
Discussion
Antenatal ultrasound markers have been used for trisomy
21 screening for over two decades [2]. First-trimester
fetuses with trisomy 21 typically exhibit increased NT
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Table 1. Indications for invasive testing for karyotype 
analysis
Indication n (%)
Advanced maternal age and/or 31 (53)
maternal anxiety
Increased risk in combined screening test 18 (31)
Previous infant with malformation 3 (5)
Previous infant with trisomy 21 3 (5)
Balanced translocation in parent 1 (2)
Determination of acetylcholinesterase 1 (2)
Previous infant with DMD 1 (2)
Total 58 (100)
DMD = Duchenne muscular dystrophy.
Table 2. Combined test risk in patients with ductus 
venosus (DV) waveform, tricuspid regurgitation (TR), 
and abnormal DV flow plus TR
Combined test risk
> 1 in 300 < 1 in 300
DV flow
Abnormal 6 1
Normal 12 39
TR
Present 5 1
Absent 13 39
Abnormal DV flow + TR
Both abnormal 5 –
Other 14 39
and an absence of nasal bone in about 75% and 70% of
cases, respectively. Recent research has led to the inclu-
sion of various ultrasound markers for first-trimester
trisomy 21 detection [2]. DV Doppler waveform analy-
sis and TR can have significant implications within this
context. The first-trimester combined test (NT plus
PAPP-A plus free β-hCG) is widely employed as a screen-
ing tool, with considerable accuracy [8,13]. DV and
TR studies are usually reserved for determining the need
for invasive testing in intermediate-risk pregnancies (i.e.
1 in 100 to 1 in 1,000).
We speculated that DV and/or TR ultrasound stud-
ies at 11–14 weeks of gestation could predict a high-risk
combined test result (i.e. > 1 in 300), and the present
pilot study was, therefore, performed. Pregnancies with
abnormal karyotypes or fetal malformations were ex-
cluded, as the aim was to obtain preliminary data based
on a limited number of women that could provide the
basis for further research. The results indicated high
specificities and PPVs with low false-positive rates for
DV and TR investigations. Neither marker appeared to
be superior to the other. Moreover, all pregnancies with
an abnormal DV flow accompanied by TR fell in the
risk-group (> 1 in 300), yielding a PPV of 100% and a
false-positive rate of 0%. The combined screening
method, thus, provided no additional information when
both DV and tricuspid flow were abnormal.
The low sensitivity observed in the current study
was a matter for concern. Sensitivity is generally expected
to be low when specificity is high, as in our data. Low
sensitivity can also occur if the cut-off value is set 
too high. However, we believe that reducing the cut-
off value in this study would be clinically unrealistic,
and would increase the false-positive rate. More false-
positive results would suggest more high-risk tests (that
are in fact below the cut-off value), thus leading to
more invasive tests.
A possible limitation in this study was its inability
to directly investigate the relationship between DV flow
or TR and fetal karyotype abnormalities. The dataset
had insufficient power to predict abnormal karyotype
results. The relatively high rates of abnormal DV flow
and TR (12% and 10%, respectively) in a healthy popu-
lation could also be a matter of concern. Abnormal
DV flow has been reported in 3–5% of otherwise nor-
mal fetuses [4,11,14], while the corresponding rate for
TR is 3–9% [4,10,12]. The relatively high rates encoun-
tered in the current study can be attributed to the
inclusion of a selected invasively karyotyped popula-
tion. This could have caused a bias in the results, as
PPV increases with the prevalence of a given condition.
However, the low false-positive rate should be unaf-
fected, as specificity does not depend on the prevalence.
The reason why some otherwise healthy fetuses show
abnormal DV Doppler waveforms at 11–14 weeks’ ges-
tation is unknown; possible causes include cardiac pre-
load or afterload changes over time, or relatively distal
communication of the DV with the inferior vena cava
in those fetuses.
Matias et al [11] were the first to emphasize the
relationship between abnormal a wave flow in the DV
and chromosomal abnormalities. About 90% of chro-
mosomally abnormal fetuses showed an abnormal DV
flow pattern, indicating a role for DV flow Doppler stud-
ies in reducing false-positive results and decreasing
unnecessary interventions. The feasibility of DV wave-
forms has been investigated in several other studies
[14–21]. An abnormal DV flow has been found to be
particularly valuable in pregnancies with an abnormal
NT measurement. The combined use of DV flow and
NT has demonstrated 95% sensitivity, with a 0.08 neg-
ative likelihood ratio [14].
The tricuspid valve can be adequately observed dur-
ing 11–14 week ultrasound scans in 96–98% of the gen-
eral population, depending on the instrument used and
the technical skill of the sonographer [10,12]. TR dur-
ing the first-trimester scan seems to be significantly
associated with karyotype abnormalities. TR is also a
predictor of fetal cardiac pathology, even in the absence
of chromosomal defects [10,12]. However, the defini-
tion of TR has not been standardized; some authors use
a minimum regurgitation velocity of 80 cm/s [13,22],
whereas others have used values > 60 cm/s as “abnor-
mal”. In the current study, abnormal tricuspid flow was
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Table 3. Efficacy of ultrasound parameters for the prediction of increased risk (> 1 in 300) in first-trimester screening 
test*
Sensitivity Specificity PPV NPV FNR FPR AR LR (+) LR (–)
Abnormal DV flow 33.3 97.5 85.7 76.4 66.6 2.5 77.5 13.3 0.68
TR 27.7 97.5 83.3 75 72.2 2.5 75.8 11.1 0.74
Abnormal DV flow + TR 26.3 100 100 73.5 73.6 0 75.8 – 0.73
*Data are presented as percentages. PPV = positive predictive value; NPV = negative predictive value; FNR = false-negative rate; FPR = false-positive rate;
AR = accuracy rate; LR = likelihood ratio; + = positive; − = negative; DV = ductus venosus; TR = tricuspid regurgitation.
regarded as a velocity of > 60 cm/s for maximal regur-
gitation.
Data on the combined use of DV flow and TR in
first-trimester fetuses are scarce. A multicenter study [8]
classified pregnancies into three groups, depending on
the first-trimester screening test results: high risk (> 1
in 100), moderate risk (1 in 100 to 1 in 1,000), and
low risk (< 1 in 1,000) pregnancies. Women in the
“high-risk” group were directly offered invasive testing,
whereas “low-risk” pregnancies were observed expec-
tantly. First-trimester ultrasound markers (nasal bone,
DV flow, and TR studies) were reserved for “moderate”
risk women, and the risk was modified accordingly.
The decision to perform further invasive testing, there-
fore, depended on these ultrasound markers. This two-
step (contingent) evaluation was associated with a
sensitivity of over 90% for the detection of trisomy 21.
Interestingly, the independent sensitivities of abnormal
DV flow and TR were also high (94.2% and 91.7%,
respectively). In the current study, all women with an
abnormal DV flow (n = 7) and TR (n = 6) were offered
invasive testing, although the final decision did not
depend on these ultrasound parameters, and the physi-
cian in charge of the woman was blinded to the DV
flow and TR results in most cases. Abnormal DV flow
and TR were associated with increased risk in six out of
seven (86%) and five out of six (83%) women, respec-
tively. Interestingly, none of the women who were not
initially offered invasive testing (and, therefore, excluded
from the study) had abnormal DV or tricuspid flow
results (data not shown). The preliminary findings of
this study, thus, support the use of these two parame-
ters as a first line of investigation.
Despite these advantages, determination of DV flow
and TR in first-trimester fetuses can be technically dif-
ficult and time consuming. Although DV Doppler wave-
forms can be obtained relatively easily, tricuspid valve
studies are difficult and involve a learning curve. Deter-
mination of these two markers has been suggested to
require expert skills and training, thus restricting their
routine use in an unselected population [5]. However,
intra- and interobserver values of DV flow have been
reported to be satisfactory in at least one study [23].
Similarly, tricuspid flow could be detected in 98.8% of
cases in a study that included 12 obstetricians experi-
enced in fetal cardiac scanning [10]. The same study
also examined the consensus among pediatric cardiol-
ogists and obstetricians performing the scan; there
was an 88% agreement rate when TR was positive, and
a 97% agreement rate in the absence of TR [10].
In conclusion, abnormal DV flow and TR detected
during the 11–14-week scan is associated with low sensi-
tivity but high PPV and low false positivity for predicting
increased risk identified by the routine combined screen-
ing test for trisomy 21. The utility of DV and tricuspid
flow as initial markers of trisomy 21 risk in unselected
pregnancies warrants further investigation.
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